Cyclooxygenase variants and methods of use

Details Cyclooxygenase variants and methods of use Cyclooxygenase variants and methods of use

2007-02-20

2007-02-20

Saidha, Tekchand (Department: 1652)

Chemistry: molecular biology and microbiology

Enzyme , proenzyme; compositions thereof; process for...

Oxidoreductase

C435S252300, C435S320100, C435S440000, C435S004000, C435S006120, C435S018000, C435S325000, C435S069100, C435S071100, C536S023200, C536S023500, C514S789000

Reexamination Certificate

active

10260937

ABSTRACT:
The invention relates to the isolation of novel cyclooxygenase type 1 (COX-1) variant enzymes. More specifically, the invention relates to the identification of cyclooxygenase transcripts harboring inton 1, or fragment thereof, of cyclooxygenase 1. The invention further relates to the diagnosis of aberrant cyclooxygenase type 1 variant gene or gene product; the identification, production, and use of compounds which modulate cyclooxygenase type 1 variant gene expression or the activity of the cyclooxygenase type 1 variant gene product including but not limited to nucleic acid encoding cyclooxygenase type 1 variants and homologues, analogues, and deletions thereof, as well as antisense, ribozyme, triple helix, antibody, and polypeptide molecules as well as small inorganic molecules; and pharmaceutical formulations and routes of administration for such compounds.

REFERENCES:
patent: 5543297 (1996-08-01), Cromlish et al.
patent: 5643960 (1997-07-01), Breitner et al.
patent: 6025395 (2000-02-01), Breitner et al.
patent: 6048850 (2000-04-01), Young et al.
patent: 6107087 (2000-08-01), O'Neill et al.
patent: 6187756 (2001-02-01), Lee et al.
patent: 6638744 (2003-10-01), Wisnewski et al.
patent: 2002/0064845 (2002-05-01), Wisnewski et al.
patent: 01-228479 (1989-09-01), None
patent: 10324698 (1998-03-01), None
patent: WO 01/11026 (2001-02-01), None
patent: WO 01/55320 (2001-08-01), None
patent: WO 01/90125 (2001-11-01), None
patent: WO 02/071928 (2002-09-01), None
Vogiagis et al., Cyclooxygenase-1 and an alternatively spliced mRNA in the rat stomach: effects of aging and ulcers, Am J Physiol Gastrointest Liver Physiol, May 2000, vol. 278, No. 5, pp. G820-827.
Funk et al., P2319, NCBI, 1991.
Ballou, et al., “Nociception in cyclooxygenase isozyme-deficient mice”,Proc. Natl. Acad. Sci., 97(18):10272-10276 (2000).
Botting, “Mechanism of action of acetaminophen: is there a cyclooxygenase 3?”,Clin. Infect. Dis., 31(Suppl. 5):S202-10 (2000).
Breitner, et al., “Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs”,Neurobiology of Aging, 16(4):523-530 (1995).
DeWitt, et al., “PGH synthase isoenzyme selectivity: The potential for safer nonsteroidal antiinflammatory drugs”,Amer. J. Med., 95(Suppl. 2A):40S-44S (1993).
Griffin, et al., “Brain interleukin 1 and S-100 immunoreactivity are elevated in Down Syndrome and Alzheimer disease”,Proc. Natl. Acad. Sci., 88:7611-7615 (1989).
Herschmann, et al., “TIS10, a mitogen-inducible glucocorticoid-inhibited gene that encodes a second prostaglandin synthase/cyclooxygenase enzyme”,J. Lipid Mediators, 6:89-99 (1993).
Hla & Neilson, “Human cyclooxygenase-2 cDNA”,Proc. Natl. Acad. Sci., 89:7384-7388 (1992).
Jang, et al., “Cancer chemopreventive activity of resveratrol, a natural product derived from grapes”,Science, 275:218-220 (1997).
Johnson, et al., “Complement mRNA in the mammalian brain: Responses to Alzheimer's disease and experimental brain lesioning”,Neurobiol. Aging, 13:641-648 (1992).
Lipsky, P.E. & Isakson, P.C., “Outcome of Specific COX-2 Inhibition in Rheumatoid Arthritis”,Journal of Rheumatol., 24(Suppl. 49):9-14 (1997).
Masferrer, et al., “Selective inhibition of inducible cyclooxygenase 2in vivois antiinflammatory and nonulcerogenic”,Proc. Natl. Acad. Sci., 91:3228-3232 (1994).
McGeer, P.L. & Rogers, J., “Anti-inflammatory agents as a therapeutic approach to Alzheimer's disease”,Neurology, 42(2):447-449 (1992).
McGeer, P.L., & McGeer, E.G., “The inflammatory system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases”,Brain Res. Rev., 21(2):195-218 (1995).
McGeer, et al., “Anti-inflammatory drugs and Alzheimer's disease”, The Lancet, 335(8696):1037 (1990).
Schnabel, J., “New Alzheimer's Therapy Suggested”,Science, 260(5115):1719-1720 (1993).
Simmons, et al., “Drug inhibition and cellular regulation of prostaglandin G/H synthase isoenzyme 2”,J. Lipid Mediators, 6:113-117 (1993).
Vane, “Towards a better aspirin”,Nature, 367(6460):215 (1994).
Xie, et al., “Expression of mitogen-responsive gene encoding prostaglandin synthase in regulated by mRNA splicing”,Proc. Natl. Acad. Sci., 88:2692-2696 (1991).
Yamagata, et al., “Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids”,Neuron, 11(2):371-386 (1993).
Wang, L-H et al. “Characterization of the promoter of human prostaglandin H synthase-1 gene”Biochem. Biophys. Res. Commun.190:406-411 (1993).
Treisman et al. EMBL database accession No. P1; T13049 (1999).
Takahashi Y et al. “Immunoaffinity Purification and cDNA Cloning of Human Platelet Prostaglandin Endoperoxide Synthase (Cyclooxygenase)”Biochem. Biophys. Res. Commun., 182: 433-438 (1992).

Affiliated with

Also associated with

Rating

Cyclooxygenase variants and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cyclooxygenase variants and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclooxygenase variants and methods of use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3849092